SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Segment Net Sales
United States	$	907.5	$	804.6	$	2,636.1	$	2,393.1
Europe	387.9		319.8		1,107.9		978.0
Japan	90.1		81.4		267.2		253.9
Rest of World	167.6		148.6		486.8		428.7
Total segment net sales	$	1,553.1	$	1,354.4	$	4,498.0	$	4,053.7
Cost of Sales
United States	$	167.1	$	126.6	$	480.6	$	412.7
Europe	82.4		72.7		249.4		220.7
Japan	13.3		11.7		39.2		36.1
Rest of World	40.8		41.0		124.5		119.7
Total segment cost of sales	$	303.6	$	252.0	$	893.7	$	789.2
Selling, general, and administrative expenses
United States	$	140.2	$	126.2	$	409.1	$	359.2
Europe	70.0		65.0		217.6		207.3
Japan	17.9		17.7		52.8		63.3
Rest of World	49.5		43.1		139.9		131.1
Total segment selling, general, and administrative expenses	$	277.6	$	252.0	$	819.4	$	760.9
Other Segment Items
United States	$	0.7	$	0.6	$	1.9	$	2.0
Europe	28.9		4.8		35.8		9.7
Japan	(0.9)		(2.4)		(5.7)		(5.3)
Rest of World	(4.7)		(2.7)		(21.8)		(6.8)
Total other segment items (a)	$	24.0	$	0.3	$	10.2	$	(0.4)
Segment Operating Income
United States	$	599.5	$	551.2	$	1,744.5	$	1,619.2
Europe	206.6		177.3		605.1		540.3
Japan	59.8		54.4		180.9		159.8
Rest of World	82.0		67.2		244.2		184.7
Total segment operating income	$	947.9	$	850.1	$	2,774.7	$	2,504.0

_______________________________________________________________________________

(a)    Other segment items include research and development expenses and foreign currency.

The table below presents a reconciliation of segment operating income to consolidated pre-tax income (in millions):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Pre-tax Income Reconciliation
Segment operating income	$	947.9	$	850.1	$	2,774.7	$	2,504.0
Unallocated amounts:
Corporate items	(510.5)		(468.7)		(1,501.9)		(1,396.5)
Separation costs (Note 3)	(0.1)		(32.9)		(8.5)		(32.9)
Intangible assets impairment charges	(40.0)		—		(40.0)		—
Certain litigation expenses	(90.4)		(10.8)		(116.8)		(27.8)
Change in fair value of contingent consideration liabilities	12.5		—		12.5		—
Foreign currency	(12.3)		12.9		(6.9)		19.3
Consolidated operating income	307.1		350.6		1,113.1		1,066.1
Non-operating income	41.3		52.2		69.4		91.9
Consolidated pre-tax income	$	348.4	$	402.8	$	1,182.5	$	1,158.0

Schedule of Enterprise-Wide Information

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement	$	1,149.9	$	1,023.3	$	3,327.4	$	3,069.8
Transcatheter Mitral and Tricuspid Therapies	145.2		91.1		394.9		247.0
Surgical Structural Heart	258.0		240.0		775.7		736.9
	$	1,553.1	$	1,354.4	$	4,498.0	$	4,053.7